The anticancer activity of SGLT-2 inhibitors has been demonstrated in such cancers as liver, pancreatic, prostate, bowel, lung and breast cancer [1,2,3,4,5,6,7,8,9,10,11]. Here, SLC5A2 is linked to breast cancer.